FLT3 is a receptor tyrosine kinase that has been shown to play a role in proliferation and survival of hematopoietic progenitor cells as well as differentiation of early B lymphoid progenitors (1). FLT3 consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. FLT3 is the most frequently mutated gene in cases of acute myelogenous leukemia (AML). About 30% to 35% of patients have either internal tandem duplications (ITDs) in the juxtamembrane domain or mutations in the activating loop of FLT3 (2). The consequence of either FLT3-ITD or activating loop mutations is the constitutive activation of the tyrosine kinase activity.
FLK2, STK1, CD135
1. Christensen, J L. et al : Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc. Nat. Acad. Sci. 98: 14541-14546, 2001.
2. Gilliland, D G. et al: Role of FLT3 in leukemia. Curr Opin Hematol. 2002 Jul;9(4):274-81.
Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.
Sample Purity Data. For specific information on a given lot, see related technical data sheet.
Storage, Stability and Shipping:
Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Krejci Pavel et al., NF449 Is a Novel Inhibitor of Fibroblast Growth Factor Receptor 3 (FGFR3) Signaling Active in Chondrocytes and Multiple Myeloma Cells Journal of Biological Chemistry July 2010 10.1074/jbc.M109.083626
JW Singer et al., Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. Journal of Experimental Pharmacology August 2016 10.2147/JEP.S110702
AKT/PKB Pathway, Angiogenesis, Cancer, ERK/MAPK Pathway, Receptor Tyrosine Kinases